Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2018 Business and Financial Update on March 27, 2019
|Date||Wednesday, March 27, 2019|
|Time||5:00 p.m. EDT|
|Toll free (U.S.)||(866) 672-5029|
|Webcast (live and replay)||www.osmotica.com under the “Investor & News” section|
A replay of the conference call will be available for one week after the call's completion by dialing (855) 859-2056 (US) or (404) 537-3406 (International) and entering conference call ID 2286829. The webcast will be archived for 30 days at the aforementioned URL.
Osmotica has a late‑stage development pipeline highlighted by two NDA candidates in Phase III clinical trials: arbaclofen extended‑release tablets for spasticity in multiple sclerosis patients and RVL‑1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid.
Osmotica has operations in
Investor and Media Relations for
In-Site Communications, Inc.
Source: Osmotica Pharmaceuticals plc